
    
      On 31-May-2016 Novartis's made the decision decision to not open the Phase II portion of the
      study, for business reasons. Sufficient data had already been collected and no additional
      data for the triplet combinations was needed. As a result, the Phase II portion of the trial
      was not opened.
    
  